4C LABSCare
Commitment
Choice
Change
Care
Commitment
Choice
Change
Care
Commitment
Choice
Change
Care
Commitment
Choice
Change
Improving patient care by providing access to medical cannabis.
4C LABS team includes Hannah Deacon, who has publicly championed access to cannabis based products for treatment of refractory epilepsies in Pediatrics. 4C LABS will work with patients and physicians to improve accessibility and availability for those who need treatment the most.
Developing Medical Cannabis products to the highest standards of safety and efficacy.
UK patients deserve access to medicines that have been tested, certified and grown organically using proven cannabis genetics. With a deep understanding of plant genetics and innovative dosing strategies, 4C LABS delivers custom tailored solutions to address patients’ specific needs.
An extensive database of cannabis genetics enables 4C LABS to provide a unique product selection.
4C LABS’ cultivation strategy is spear-headed by a Canadian Master Grower with 25+ years experience supplying sought after products to compassion centres that serve the cancer community and others who suffer from chronic illnesses
Seeking to destigmatise through education and access enabled by digital technologies.
4C LABS is building a data analytics platform that enables innovative product development. In turn, our partnership with the Medical Cannabis Clinicians Society broadens our educational reach and network within the UK medical community.
